CDCA7L anticorps (C-Term)
Aperçu rapide pour CDCA7L anticorps (C-Term) (ABIN1881189)
Antigène
Voir toutes CDCA7L AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
Clone
-
-
Épitope
- AA 290-317, C-Term
-
Purification
- This antibody is purified through a protein A column, followed by peptide affinity purification.
-
Immunogène
- This CDCA7L antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 290-317 amino acids from the C-terminal region of human CDCA7L.
-
Isotype
- Ig Fraction
-
-
-
-
Indications d'application
- WB: 1:1000
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- 4 °C,-20 °C
-
Date de péremption
- 6 months
-
-
-
: "Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells." dans: Cancer research, Vol. 65, Issue 13, pp. 5607-19, (2005) (PubMed).
: "R1, a novel repressor of the human monoamine oxidase A." dans: The Journal of biological chemistry, Vol. 280, Issue 12, pp. 11552-9, (2005) (PubMed).
: "Human chromosome 7: DNA sequence and biology. ..." dans: Science (New York, N.Y.), Vol. 300, Issue 5620, pp. 767-72, (2003) (PubMed).
-
-
- CDCA7L (Cell Division Cycle Associated 7-Like (CDCA7L))
-
Autre désignation
- CDCA7L
-
Sujet
- Plays a role in transcriptional regulation as a repressor that inhibits monoamine oxidase A (MAOA) activity and gene expression by binding to the promoter. Plays an important oncogenic role in mediating the full transforming effect of MYC in medulloblastoma cells. Involved in apoptotic signaling pathways, May act downstream of P38-kinase and BCL-2, but upstream of CASP3/caspase-3 as well as CCND1/cyclin D1 and E2F1.
-
UniProt
- B3KTR5
Antigène
-